Volume 19, Number 9—September 2013
Research
Plasmodium falciparum Mutant Haplotype Infection during Pregnancy Associated with Reduced Birthweight, Tanzania
Table 1
Participant exposure to SP | No. (%) women with infecting allelic haplotype |
||
---|---|---|---|
Quadruple or less, n = 5 | Quintuple, n = 25 | Sextuple, n = 24 | |
Did not receive IPTp–SP (n = 28) | 4 (14.3) | 12 (42.9) | 12 (42.9) |
Received first dose of IPTp–SP (n = 18) | 1 (5.6) | 8 (44.4) | 9 (50.0) |
Received second dose of IPTp–SP (n = 8) | 0 | 5 (62.5) | 3 (37.5) |
Had previous exposure to SP (n = 30)† | 1 (3.3) | 16 (53.0) | 13 (43.0) |
*SP, sulfadoxine–pyrimethamine; IPTp–SP, intermittent preventive treatment during pregnancy with SP.
†Received IPTp-SP or SP used as treatment for malaria before study inclusion.
1Current affiliation: Mère et Enfant Face aux Infections Tropicales, Paris, France.
Page created: July 23, 2013
Page updated: August 20, 2013
Page reviewed: August 20, 2013
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.